tiprankstipranks
Serina Therapeutics Strengthens Board with New Appointment
Company Announcements

Serina Therapeutics Strengthens Board with New Appointment

Story Highlights

Invest with Confidence:

Serina Therapeutics ( (SER) ) just unveiled an update.

On January 14, 2025, Serina Therapeutics announced the appointment of Karen J. Wilson to its Board of Directors, marking a significant addition due to her extensive experience in the life sciences sector. Wilson’s financial and industry expertise is expected to support Serina’s strategic initiatives and enhance its positioning in the biotechnology market. Concurrently, Steven Mintz departed from the board, with Remy Gross taking over as the chair of the Audit Committee.

More about Serina Therapeutics

Serina Therapeutics is a clinical-stage biotechnology company based in Huntsville, Alabama, focusing on developing drug product candidates to treat neurological diseases and other indications. Their proprietary POZ Platform™ is used to enhance drug delivery, offering potential improvements in efficacy and safety for small molecules, RNA-based therapeutics, and antibody-drug conjugates. The company is also exploring partnerships to expand the applications of its POZ technology.

YTD Price Performance: -3.92%

Average Trading Volume: 26,931

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $43.57M

See more insights into SER stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles